KLA Corporation Stock (KLAC) Week Ahead Outlook: Analyst Upgrades, AI Equipment Forecasts, and What to Watch Dec. 22–26, 2025

KLA Corporation Stock (KLAC) Week Ahead Outlook: Analyst Upgrades, AI Equipment Forecasts, and What to Watch Dec. 22–26, 2025

Updated for the week ahead (Dec. 22–26, 2025). KLA Corporation (NASDAQ: KLAC) enters the Christmas-shortened trading week with momentum from fresh Wall Street upgrades and a strengthening top-down narrative: the AI infrastructure buildout is keeping semiconductor capital spending—especially at the
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely
Philip Morris International (PM) Stock Week Ahead: Dividend Watch, FDA Nicotine Pouch Developments, Analyst Targets and Key Catalysts for Dec. 22–26, 2025

Philip Morris International (PM) Stock Week Ahead: Dividend Watch, FDA Nicotine Pouch Developments, Analyst Targets and Key Catalysts for Dec. 22–26, 2025

Published: Sunday, Dec. 21, 2025 (week-ahead outlook) Philip Morris International Inc. (NYSE: PM) heads into the Christmas-shortened trading week with a familiar mix of forces: a defensive consumer-staples profile, an income-driven shareholder base watching the next dividend milestone, and an
Go toTop